West Pharmaceutical Services (WST) Raised Guidance, Is It Still 16% Undervalued?
Why West Pharmaceutical Services Stock Is Back In Focus After Q2
West Pharmaceutical Services (WST) is back on investors radar after reporting second quarter 2026 results, raising its full year revenue outlook and updating shareholders on recent buyback and dividend activity.
See our latest analysis for West Pharmaceutical Services.
At a latest share price of US$340.96, West Pharmaceutical Services has seen a 13.4% 90 day share price return and a 23.4% year to date share price return. The 1 year total shareholder return of 43% points to building momentum as the market responds to higher revenue guidance, steady dividends and continued buybacks.
If this kind of renewed interest has you looking beyond West Pharmaceutical Services, it could be a good time to broaden your search and check out 41 healthcare AI stocks.
West Pharmaceutical Services looks like a high quality business, backed by rising revenue guidance, solid recent earnings and active buybacks. After the latest share price jump, investors may question whether that strength still comes at a reasonable valuation.
Most Popular Narrative: 16% Undervalued
The most followed narrative on West Pharmaceutical Services points to a fair value of about $404 compared with the latest share price of $340.96. That gap rests on specific forecasts for revenue, margins and the price investors might be willing to pay for future earnings.
The continued growth in GLP-1s, which made up about 7% of total revenues in the first quarter, and the company's ability to capitalize on significant opportunities in this market could drive revenue and earnings growth. The increase in demand and the transition to higher-margin HVP components, supported by approximately 340 Annex 1 projects, is likely to positively impact both revenue and net margins due to a favorable mix shift.
Want to see what sits behind that fair value for West Pharmaceutical Services? The narrative leans on expectations for revenue expansion, wider margins and a premium earnings multiple that still assumes some rerating from today.
Result: Fair Value of $404 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, West Pharmaceutical Services still faces the risk that shifting demand for high value components and higher tariffs could pressure margins and challenge the current growth narrative.
Find out about the key risks to this West Pharmaceutical Services narrative.
Another View On West Pharmaceutical Services Valuation
The first narrative points to West Pharmaceutical Services trading about 16% below an estimated fair value of $404. However, the current P/E of 42.5x is nearly double the fair ratio of 21.9x, and above the global Life Sciences average of 37.2x. That gap signals valuation risk if expectations slip even slightly.
For a closer look at what the current multiple implies for future returns and how it compares to peers, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of optimism and caution around West Pharmaceutical Services resonates with you, now is a good time to review the full picture and see what stands out most. To understand what some investors are excited about, start with the 3 key rewards.
Looking For More Investment Ideas Beyond West Pharmaceutical Services?
If West Pharmaceutical Services has sharpened your focus, you can keep that momentum going by scanning other opportunities where quality, value and resilience might align with your portfolio.
Use the Simply Wall St screener to quickly surface fresh ideas that match your style, then compare them with West Pharmaceutical Services while this earnings story is still front of mind.
- Target dependable cash generators and put potential compounding income on your radar with 9 dividend fortresses.
- Hunt for quality businesses that the market may be pricing too low right now by checking the 55 high quality undervalued stocks.
- Prioritise capital protection and steadier portfolios by reviewing the 81 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com